We evaluated the association of Human Pegivirus (HPgV) viraemia with risk of developing lymphoma, overall and by major subtypes. Because this virus has also been associated with better prognosis in the setting of coinfection with human immunodeficiency virus, we further assessed the association of HPgV with prognosis. We used risk factor data and banked plasma samples from 2094 lymphoma cases newly diagnosed between 2002 and 2009 and 1572 frequency-matched controls. Plasma samples were tested for HPgV RNA by reverse transcription polymerase chain reaction (RT-PCR), and those with RNA concentrations <5000 genome equivalents/ ml were confirmed using nested RT-PCR methods. To assess the role of HPgV in lymphoma prognosis, we used 2948 cases from a cohort study of newly diagnosed lymphoma patients (included all cases from the case-control study). There was a positive association of HPgV viraemia with risk of lymphoma overall (Odds ratio = 2Á14; 95% confidence interval [CI] 1Á63-2Á80; P < 0Á0001), and for all major subtypes except Hodgkin lymphoma and chronic lymphocytic leukaemia/small lymphocytic lymphoma, and this was not confounded by other lymphoma risk factors. In contrast, there was no association of HPgV viraemia with event-free survival (Hazard ratio [HR] = 1Á00; 95% CI 0Á85-1Á18) or overall survival (HR = 0Á97; 95% CI 0Á79-1Á20) for lymphoma overall, or any of the subtypes. These data support the hypothesis for a role of HPgV in the aetiology of multiple lymphoma subtypes.
autoimmune disorders and exposure to physical, chemical and infectious agents (Cerhan et al, 2018) . Among the latter, several recent studies suggest an association between a common, otherwise non-pathogenic virus, called human pegivirus (HPgV), and NHL (Krajden et al, 2010; Chang et al, 2014) .
HPgV was initially called by two names when it was discovered in 1995, GB virus type C (GBV-C) (Simons et al, 1995) and hepatitis G virus (HGV) (Linnen et al, 1996) . As it was shown not to cause hepatitis or any other known illness, nor was infection identified in the presumed hepatitis patient with the initials 'GB', neither name accurately described the virus, and it was re-classified as a member of the Pegivirus genus within the Flaviviridae (Stapleton et al, 2011; Adams et al, 2013; Simmonds et al, 2017) . HPgV is a single-stranded RNA virus that is transmitted through parenteral, sexual and perinatal routes (Heuft et al, 1998; Mohr & Stapleton, 2009 ). Approximately 2% of healthy US blood donors are viraemic with HPgV at the time of blood donation, while individuals with sexually transmitted infections and human immunodeficiency virus (HIV), and intravenous drug users have a much higher rate of exposure and viraemia, with a cross-sectional viraemia prevalence of approximately 20% (Mohr & Stapleton, 2009) .
Phylogenetically, HPgV is the most closely related human virus to Hepatitis C virus (HCV), which is also associated with risk of NHL (Engels et al, 2004; Matsuo et al, 2004; Giordano et al, 2007; Simmonds et al, 2017) . Active HPgV infection may persist for decades, although the majority of infections clear within 2 years in immune competent hosts (Tacke et al, 1997; Thomas et al, 1997; Tillmann et al, 1998) . HPgV infection is detected by nucleic acid amplification of viral RNA from plasma or serum (Simons et al, 1995; Linnen et al, 1996) . The reason for the lack of hepatic disease presumably relates to its tissue tropism, as HPgV does not appear to replicate in the liver, and based on both ex vivo and in vitro studies it replicates in B and T lymphocytes, including CD4+ and CD8+ lymphocytes, spleen, and bone marrow (Laskus et al, 1998; Berg et al, 1999; Fan et al, 1999; Tucker et al, 2000; Xiang et al, 2000; George et al, 2003 George et al, , 2006 Jablonska et al, 2013; Kisiel et al, 2013; Chivero et al, 2014; Bailey et al, 2015) . Persistent infection among HIVinfected individuals is highly associated with impaired T-cell receptor and interleukin 2 receptor (IL2R) signalling, resulting in inhibition of T cell apoptosis, and impaired T cell activation and proliferation that may contribute to lymphomagenesis (Moenkemeyer et al, 2008; Stapleton et al, 2009 Stapleton et al, , 2012 Bhattarai et al, 2012 Bhattarai et al, , 2013 Lanteri et al, 2015) .
Because HPgV may cause persistent infection, alters immune function, and is related to HCV, a number of epidemiological studies have been conducted to determine if there is a relationship between HPgV infection and risk of NHL. Several case-control studies initially reported an association of HPgV with NHL, but conclusions were limited due to small sample sizes, use of convenience sample control groups, and combining HPgV viraemia and prior infection (Minton et al, 1998; De Renzo et al, 2002; Kaya et al, 2002; Giannoulis et al, 2004; Zignego et al, 2007) . One carefully designed, population-based study of 553 cases and 438 controls from British Columbia reported a 2Á7-fold higher risk of NHL with HPgV viraemia after accounting for other risk factors [95% confidence interval (CI) 1Á22-6Á69] (Krajden et al, 2010) , and a case-control study nested within the prospective Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial cohort (658 cases and 1316 controls) confirmed an association [Odds ratio (OR) = 3Á43, 95% CI 1Á35-8Á71] using pre-diagnosis, banked samples (Chang et al, 2014) .
To further address the association of HPgV and risk of developing lymphoma, we conducted the largest study to date of over 2000 lymphoma cases and 1500 controls. We also correlated HPgV status with circulating cytokine levels in a subset of cases and controls (Charbonneau et al, 2012) . Finally, because the virus has also been associated with prolonged survival in the setting of co-infection with HIV Toyoda et al, 1998; Lefrere et al, 1999; Yeo et al, 2000; Tillmann et al, 2001; Xiang et al, 2001; Nunnari et al, 2003; Williams et al, 2004; Zhang et al, 2006; Schwarze-Zander et al, 2010; Vahidnia et al, 2012) , we assessed the association of HPgV with event-free (EFS) and overall (OS) survival for the major lymphoma subtypes.
Methods

Study populations
All subjects provided written, informed consent and all studies were approved by the Human Subjects Institutional Review Boards of the Mayo Clinic and the University of Iowa.
Molecular Epidemiology Resource (MER) Cohort Study
The MER Cohort Study of the Iowa/Mayo Lymphoma Specialized Program of Research Excellence (SPORE) has been previously described (Cerhan et al, 2017) . Briefly, from 1 September 2002 to 30 June 2015, we prospectively offered enrolment to all consecutive patients with lymphoma who were within 9 months of their initial diagnosis at presentation, aged 18 years and older, and had no prior history of lymphoma, leukaemia or HIV/acquired immunodeficiency syndrome (AIDs); 6972 participated (5256 at Mayo and 1716 at Iowa). At enrolment, participants completed a medical history questionnaire, provided a blood specimen (for DNA, plasma and serum), and consented for access to their medical records. Serum and plasma were stored at À70°C. Clinical and treatment data were abstracted, and pathology was centrally reviewed by a haematopathologist to confirm the diagnosis and to provide a lymphoma subtype according to the World Health Organization Classification of Neoplastic Diseases of the Haematopoietic and Lymphoid Tissues (Jaffe et al, 2001; Swerdlow et al, 2008) . All participants were contacted every 6 months for the first 3 years after diagnosis and then annually thereafter to ascertain outcomes; disease progression/relapse, retreatment, transformation, new cancers and cause of death were validated against medical records.
Case-control study
The Mayo Clinic Case-Control study of Lymphoma has been previously described (Cerhan et al, 2011) . Briefly, cases were Mayo patients enrolled into the MER from 1 September 2002 to 31 August 2014 who were residents of Minnesota, Iowa and Wisconsin at the time of diagnosis (n = 3214). All of these cases are a subset of the full MER cohort described in the previous section; the MER cases from Iowa did not have risk factor data or a matched control group and were thus not eligible. We recruited controls from Mayo Clinic Rochester patients with prescheduled general medical examinations in the Department of Medicine. A total 2489 controls with no history of lymphoma, leukaemia, or HIV/AIDS were frequency matched to the case distribution by 5-year age group, sex, and geographic location of residence. Participants completed a series of self-administered risk-factor questionnaires that included demographic data, history of hepatitis, blood transfusion, autoimmune disease, atopy, family history of lymphoma, farming, obesity, smoking, alcohol use and sun exposure.
Analysis datasets
The current analyses were based on 2948 MER cases with an available baseline plasma sample when we extracted banked samples to run the HPgV assay in 2012. Of these 2948 cases, 2094 were also in the case-control study, as were 1572 controls. Of the 2948 cases, 1296 (61Á9%) had a plasma sample collected prior to lymphoma treatment and 798 (38Á1%) were collected after initiation of treatment.
Laboratory methods
HPgV RNA extraction, detection and quantification. HPgV replication was assessed by measuring HPgV RNA in plasma by real-time reverse transcription polymerase chain reaction (RT-PCR) as described below. To enhance sensitivity compared to previous studies, two variations from reported studies were used (Souza et al, 2006; Rydze et al, 2012; Chang et al, 2014) . First, a larger volume was used for both plasma RNA extraction and in the reaction, and secondly the number of cycles of real-time PCR was increased to 45. Briefly, RNA was extracted from 560 ll of plasma using QIamp Viral RNA Mini Kit (Qiagen, Hilden, Germany), and each PCR reaction contained an 26 ll aliquot of RNA (representing 250 ll of plasma), 30 ll TaqMan Master Mix (2X) (ABI, Thermo Fisher Scientific, Waltham, MA, USA), 1Á5 ll superscript III RT platinum Taq mix, 0Á72 ll each of forward and reverse primers (50 lmol/l, Integrated DNA Technologies, Coralville, IA, USA), 0Á12 ll Taqman probe (100 lmol/l, ABI) and 0Á3 ll of Rnasin (40 U (George et al, 2003) . Quantitative one step Real Time PCR was performed using an ABI 7500 system. The running conditions were 50°C for 20 min, 95°C for 2 min, 45 cycles at 95°C for 15 s and 58°C for 1 min. A HPgV RNA quantitation standard used was prepared as described. (Rydze et al, 2012) HPgV genome sequences from nt 1 to 850 (from GenBank Accession Number AF121950; https://www.ncbi.nlm. nih.gov/nuccore/af121950) were cloned into pCR2Á1 plas mid (Invitrogen, Inc., Camarillo, CA, USA) downstream of the T7 polymerase promoter. The plasmid was linearized with Kpn1 and run off transcripts were generated (Riboprobe, Promega, Madison, WI, USA). RNA was quantified by A260/ 280, divided into 50 ll aliquots (concentration of 1 9 10 10 genome copies/ml) and stored at À80°C. For each real-time PCR experiment, a fresh aliquot was used in serial 10-fold dilutions, starting at a 1:100 dilution in RNAse-free water. Linear regression analyses of standard curves were routinely excellent (r 2 > 0Á97), and variation between cycle threshold (CT) values between experiments were within 2Á1 CT. Samples with CT values greater than 35 were repeated and further tested by nested RT-PCR as described (Souza et al, 2006) . Briefly, 26 ll RNA was amplified in a nested RT-PCR to amplify HPgV RNA using primers from either the 5 0 ntr and E2 coding regions as described (Souza et al, 2006) GAT CTT GGT CAT GG -3 0 . The sequence is based on the full-length Iowa HPgV isolate (GenBank Accession Number AF121950) (Xiang et al, 2000) . Nested RT-PCR reaction conditions were described previously, and PCR products were identified by agarose gel electrophoresis and ethidium bromide staining (Souza et al, 2006) . The 5 0 NTR and E2 amplicons were 204 nt and 304 nts in length (Souza et al, 2006) . Negative and positive controls were included with each sample undergoing PCR testing. If neither of the nested RT reactions were positive, the sample was classified as negative. If the real-time and either nested RT-PCR were positive, the sample was classified as positive.
Serum cytokine assay. In a previously published case-control study from the MER (Charbonneau et al, 2012) , we used a multiplexed assay to measure 30 cytokine concentrations in stored pre-treatment serum from 234 follicular lymphoma (FL) and 188 diffuse large B cell lymphoma (DLBCL) cases and 400 controls using a multiplex enzyme-linked immunosorbent assay (InvitrogenInc.). The cytokines were analysed using the Luminex-100 system Version 1Á7 (Luminex, Austin, TX, USA). Data were acquired using STar Station software (Applied Cytometry, Sheffield, UK) and analysis was performed using the MasterPlex QT 1Á0 system (MiraiBio, Alameda, CA, USA). Samples were randomly assigned to plates, stratified by case (DLBCL and FL) and control status, so that each plate was a mixture of cases and controls. There were 136 FL, 102 DLBCL and 379 controls with cytokine and HPgV data for analysis.
Data analysis
Case-control analyses. We used unconditional logistic regression to calculate the ORs and 95% CI to estimate the association of HPgV viraemia positivity with lymphoma risk, first adjusting for age and sex and then further adjusting for additional lymphoma risk factors. In addition to overall lymphoma risk, we also evaluated associations with the following lymphoma subtypes: HL, CLL/SLL, DLBCL, FL, mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), T cell lymphoma (TCL) and other NHL. In secondary analyses, we also evaluated the association of viraemic load with lymphoma risk, using the tertile cutpoints of viraemic positive controls for the analysis.
Survival analyses. We used Cox proportional hazards regression models to assess the association of HPgV viraemia status with EFS and OS. For all subtypes except CLL/ SLL, EFS was defined as the time from diagnosis to disease progression, retreatment, or death due to any cause; for CLL/SLL we used time to first treatment instead of EFS. OS was defined as the time from diagnosis to death due to any cause. Patients without an event or death were censored at time of last known follow-up. Correlative analysis with cytokines. We correlated cytokine levels with HPgV viraemia status using a Kruskal-Wallis rank test. We also evaluated the association of viraemic load, using the tertile cutpoints of viraemic positive controls for the analysis, with HPgV viraemia status in FL and DLBCL cases using a spearman correlation.
Results
HPgV and lymphoma risk: case-control analysis
The demographic and other selected characteristics by case and control status are reported in Table I . The mean age of cases was 61Á1 years and 58Á2% were male, while the mean age of controls was 59Á6 years and 51Á1% were male; these factors were adjusted for in all models. Cases were more likely to have a family history of NHL and a higher body mass index (BMI) at age 18 years, and were less likely to have a history of blood transfusion or ever drink alcohol.
HPgV viraemia was detected in 78 controls (5Á0%) and 211 cases (10Á1%) (P < 0Á0001). There was no major difference in the prevalence by age group or sex among both cases and controls (data not shown). Among controls, HPgV viraemia was not associated with family history of NHL, history of hepatitis, blood transfusion, BMI at age 18 years, or ever use of alcohol (Table SI) .
After adjustment for age and sex, there was a strong positive association of HPgV viraemia with risk of lymphoma overall (OR = 2Á14; 95% CI 1Á63-2Á80), and there was evidence of a trend with increasing viral load (P-trend < 0Á001) (Table II) . These associations remained after further adjustment for education, family history of NHL, history of hepatitis, blood transfusion, BMI at age 18 years and ever use of alcohol. The risk associations by lymphoma subtype are shown in Table III : there were positive associations for all subtypes except CLL/SLL (OR = 0Á90; 95% CI 0Á53-1Á53) and HL (OR = 1Á47; 95% CI 0Á76-2Á85), with the strongest association observed for FL (OR = 3Á20; 95% CI 2Á27-4Á51). For lymphoma cases, the HPgV RNA positivity was detected in 117 (9Á0%) plasma samples collected before the beginning of the treatment, and in 94 (11Á8%) samples collected after initiation of therapy (P = 0Á26). After excluding cases without pre-treatment data, there were no notable changes in the risk associations (data not shown).
HPgV viraemia and cytokine levels
To better understand potential mechanisms by which HPgV might influence lymphoma risk, we correlated circulating serum cytokines in 379 controls from a previous study (Charbonneau et al, 2012) with the newly determined HPgV viraemia status (Table SII) . As shown in Fig. 1 , serum levels of soluble IL2R, macrophage inflammatory protein-1 alpha (MIP1a) and monokine induced by gamma interferon (MIG, also termed CXCL9) were significantly higher in HPgV viraemia positive controls compared to HPgV negative controls. Pre-treatment serum cytokines were available for 136 FL and 102 DLBCL cases, but there was no association of any cytokines with HPgV viraemic status for either group (data not shown). 
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HPgV viraemia and lymphoma outcome
HPgV viraemia was not associated with EFS [Hazard ratio (HR) = 1Á00; 95% CI 0Á85-1Á18) or OS (HR = 0Á97; 95% CI 0Á79-1Á20) in lymphoma overall or with each of the major subtypes (Table IV) . For lymphoma overall, there was no association of EFS or OS with viraemic load (data not shown).
Discussion
In this clinic-based case-control study we found a positive association of HPgV infection with risk of lymphoma overall and each of the major lymphoma subtypes except CLL/SLL and HL. This study is the largest to date and was well-powered for the first robust assessment of associations with the major lymphoma subtypes of DLBCL, FL and CLL/SLL. These associations remained after adjustment for potential confounding factors. In contrast, we did not observe any associations of HPgV status with EFS or OS for any of the lymphoma subtypes.
There are limitations to our study. Samples were collected after the start of treatment in about one-third of cases, although we and others observed that this did not alter these associations (Krajden et al, 2010) . However, only pre-disease samples can definitively address this question, as discussed below. Our HPgV viraemia prevalence was much higher than in the two largest published studies (Krajden et al, 2010; Chang et al, 2014) . This is most likely explained by the use of a more sensitive HPgV RNA detection method than in B-NHL, B cell Non-Hodgkin lymphoma; BMI, body mass index; CI, confidence interval; CLL/SLL, chronic lymphocytic leukaemia/small cell lymphoma; DLBCL, diffuse large B-cell lymphoma; HPgV, human pegivirus; OR, odds ratio. *Adjusted for age, sex, education, family history of NHL, hepatitis, blood transfusion, BMI at age 18 years, and alcohol use. previous studies. Unfortunately, a reproducible antibody test is no longer commercially available, so prior infection cannot be determined in PCR negative subjects. Although we were able to adjust for a variety of potential confounding factors in the case-control study, there may be residual confounding for by other factors, and the possibility remains that patients destined to clinically develop lymphoma may have a preexisting immune alteration that reduces their clearance of HPgV infection, leading to higher viraemia rates in new lymphoma diagnoses. Also, our case-control study was clinic and not population-based, which is a weaker design, although we have shown robust internal and external validity for a variety of results from this study (Cerhan et al, 2011; Morton et al, 2014) . Finally, while we were able to adjust for disease-specific prognostic indices in our EFS and OS analyses, we were not able to adjust for treatment or other clinical factors.
Our results confirm and extend prior reports of a positive association of HPgV infection with overall lymphoma risk observed small case-control studies, the large populationbased Canadian case-control study and the nested case-control PLCO study with banked, pre-disease samples. Compared to the Canadian study (Krajden et al, 2010) , we observed a higher overall prevalence of HPgV infection (7Á8% vs. 3Á3%), and a somewhat different risk correlation according to the subtypes. In the Canadian study the association was strongest for DLBCL (OR = 5Á18, 95% CI 2Á06-13Á71; based on 12 exposed cases), and was not associated with FL (OR = 1Á24; 95% CI 0Á27-4Á49; based on 3 exposed cases), MZL (OR = 1Á02; 95% CI 0Á05-6Á03; based on 2 exposed cases) or all T-cell (OR = 1Á00; 95% CI 0Á05-5Á77; based on 1 exposed case), acknowledging the limited power for subtype associations in that study (Krajden et al, 2010) . In the PLCO Cancer Screening Trial, statistically significant associations of HPgV viraemia with NHL overall (OR = 3Á43, 95% CI 1Á35-8Á71) and with DLBCL (OR = 5Á31, 95% CI 1Á54-18Á36; based on 4 exposed cases) were observed, with suggestive associations for FL (OR = 4Á25; 95% CI 0Á89-21Á3; based on 2 exposed cases) and CLL/SLL (OR = 3Á05; 95% CI 0Á89-10Á5; based on 4 exposed cases) (Chang et al, 2014) . Importantly, the latter prospective study showed for the first time that HPgV infection precedes development of NHL by several years, and the risk appears strongest with the longest documented presence of viraemia. Of note, the low prevalence of the HPgV infection (0Á9%) in the study was probably due to the differences in age and birth cohort differences, as well as the different methods applied to detect the viral RNA (Chang et al, 2014) . We found higher levels of IL-2R, MIP1a, and MIG in HPgV positive compared to HPgV negative controls. High levels of these cytokines have been shown in other infectious and autoimmune diseases, and they were associated with risk of DLBCL and FL as reported in a prior analysis from this study (Witkowska, 2005) . It is difficult, however, to establish whether elevated levels of these cytokines promote tumour growth through immunosuppression or other mechanisms, or whether it depends on the constitutive activation of the immune cells. Although our data only suggest potential pathways through which HPgV might influence the lymphomagenesis, further studies in larger numbers of patients are needed to fully examine the role of HPgV-mediated cytokine modulation and the risk of developing NHL.
Additional biological mechanisms that may contribute to a role for HPgV viraemia in lymphomagenesis include the fact that it is a lymphotropic virus that may cause persistent infection in both T and B lymphocytes (Tucker et al, 2000; George et al, 2006; Chivero et al, 2014) . In cell lines derived from HIV-infected patients, HPgV reduces Fas-mediated apoptosis (Moenkemeyer et al, 2008) and virus impairs Tcell receptor and IL2R signalling in primary and transformed T cell lines (Bhattarai et al, , 2013 and in patients with HCV infection (Bhattarai et al, 2017) , all of which may contribute to subclinical impairment of immune surveillance and thereby increase the risk of developing NHL (Pietersma et al, 2008) . While the lack of association of HPgV with risk of CLL might temper this hypothesis, the associations of NHL subtypes with specific types of infections and/or immunosuppression (primary, transplantation, iatrogenic) have been quite heterogeneous (Cerhan et al, 2018) . HPgV also influences cytokine and chemokine gene expression in lymphocytes in vitro, and in cells obtained from infected individuals, potentially influencing immune response Stapleton et al, 2012 Stapleton et al, , 2013 Lanteri et al, 2015) . Finally, persistent lymphocyte infection could lead to DNA mutation and potentially malignant transformation. The biological reason for the lack of an association of HPgV infection with lymphoma prognosis is not known, but would suggest that HPgV does not influence lymphoma aggressiveness or that other clinical or treatment factors dominate disease progression and survival. However, a limitation of this analysis is the relatively small number of HPgV viraemia positive patients, particularly for less common subtypes, which limits the power of the survival analyses.
If this association were ultimately found to be causal, then there are potential public health considerations given an HPgV viraemia prevalence of approximately 2% in healthy blood donors (Linnen et al, 1996; Heuft et al, 1998; Mohr & Stapleton, 2009 ) and the number of blood products transfused in the US annually; more than 1000 units of HPgV infected blood are predicted to be administered to individuals daily. Further, HPgV may be a biomarker that potentially can be treated or prevented, and screening of blood donors for this infection should be considered.
In conclusion, our clinic-based case-control study confirms that HPgV infection is a risk factor for lymphoma overall and extends results to each NHL subtype except HL and CLL. Further studies are needed to clarify the biological mechanisms leading to lymphoma development.
